PTC Misses Phase III In Friedrich Ataxia, But Isn’t Giving Up
Company Ends Gene Therapy R&D, Cuts Headcount
Executive Summary
Pointing to data showing benefit in patients who completed 72 weeks of therapy, PTC thinks vatiquinone still could be viable for pediatric FA patients. Restructuring won’t affect Upstaza.